About 75 percent of people with MS (Multiple Sclerosis) report fatigue among their most disabling disease symptoms.
Medications, such as those that treat narcolepsy, behavior-based therapies and even exercise programs are often prescribed but benefits have been found to be unreliable.
When compared to patients who were enrolled in a placebo arm of a recent study those that received transcranial direct current stimulation (tDCS) were found to have about a six-point drop on a 32-point scale measuring fatigue severity, according to the findings recently published online in the Multiple Sclerosis Journal.
The exact mechanism behind tDCS is unclear and requires more research. It is thought to change the brain's cortical excitability by making it easier for neurons to fire, thereby improving connections and expediting learning that takes place during rehabilitation.
Lone Star NeuroMODULATION
LSN is targeting unmet clinical needs by creating disruptive device platforms that offer promising solutions for lowering costs, realizing higher returns and effectively addressing more therapeutic indications if adopted for medical applications.